- Entheon Biomedical Corp.’s (ENBI) expanded psychedelics genetic testing panel is now available for sale in Canada and the United States
- The Psychedelics Genetic Test Kit includes a key pharmacokinetic biomarker, the CYP2D6 gene
- The CYP2D6 ‘poor metabolizer’ gene mutation influences the metabolism of LSD, MDMA and ayahuasca causing individuals to metabolize hallucinogenics two times slower than normal
- The test also includes other relevant pharmacodynamic, pharmacokinetic and mental health risk biomarkers
- Entheon intends to implement genetic testing in its upcoming research initiatives in the near year
- Entheon Biomedical Corp.’s (ENBI) is down 11.90 per cent trading at $0.37 per share as of 2:55 p.m. EST
Entheon Biomedical Corp.’s (ENBI) expanded psychedelics genetic testing panel is now available for sale in Canada and the United States.
Through Entheon’s subsidiary, HaluGen Life Sciences Inc, the Psychedelics Genetic Test Kit includes a key pharmacokinetic biomarker, the CYP2D6 gene.
The CYP2D6 ‘poor metabolizer’ gene mutation influences the metabolism of LSD, MDMA and ayahuasca.
This can cause individuals to metabolize these hallucinogenic drugs up to two times slower than normal.
Poor metabolizers can also experience an increased duration, intensity of effect and adverse drug reactions.
The test also includes other relevant pharmacodynamic, pharmacokinetic and mental health risk biomarkers including:
HTR2A gene – This gene can impact response to serotonin, the “happiness hormone”, which is the primary mechanism of action for psychedelics such as psilocybin, LSD and DMT.
CYP2B6 gene – This gene can decrease the metabolism of ketamine for the ten to twenty percent of people who carry a specific ‘poor metabolizer’ gene variant; and
C4A, NRG1 and DISC1 genes – These genes can influence mental health risk.
HaluGen’s psychedelics pre-screening platform provides insights to better inform one’s potential psychedelic experience.
By obtaining DNA test results and data from mental-health surveys, individuals are equipped with information to make more informed decisions around their psychedelic-assisted therapy.
Entheon intends to implement genetic testing in its upcoming research initiatives in the near year.
The data from these initiatives will be used to improve the testing kit and to advance its utility for both consumers and healthcare professionals.
Entheon Biomedical Corp.’s (ENBI) is down 11.90 per cent trading at $0.37 per share as of 2:55 p.m. EST.
